• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies

  • Print
  • Share
  • E-mail

Post-Approval Studies

  • In January 2005, the oversight responsibility of the Post-Approval Studies Program was transferred to the Division of Epidemiology (DEPI) of the Office of Surveillance and Biometrics (OSB)/Center for Devices and Radiological Health (CDRH).
  • The CDRH Post-Approval Studies Program encompasses design, tracking, oversight, and review responsibilities for studies mandated as a condition of approval of a premarket approval (PMA) application, protocol development product (PDP) application, or humanitarian device exemption (HDE) application. The program helps ensure that well-designed post-approval studies (PAS) are conducted effectively and efficiently and in the least burdensome manner.
  • CDRH has established an automated, internal tracking system that efficiently identifies the reporting status of active PAS studies ordered since January 1, 2005 based on study timelines incorporated in study protocols and agreed upon by the CDRH and applicants. This system represents CDRH's effort to ensure that all PAS commitments are fulfilled in a timely manner.
  • In addition, CDRH launched this publicly available webpage to keep all stakeholders informed of the progress of each PAS. The webpage displays general information regarding each PAS, as well as the overall study status (based on protocol-driven timelines and the adequacy of the data) and the applicant's reporting status for each submission due.


Contact Information

Julie Unger
Project Manager, Post-Approval Studies Program
Food and Drug Administration
10903 New Hampshire Ave
WO66-4206v Silver Spring, MD

Phone: (301) 796-6134
Fax: (301) 847-8140

Show All Studies
Suggest Enhancement / Report Issue | Export to ExcelExport to Excel
Application Number P090013
Current Protocol Accepted 02/08/2011
Study Name OSB Lead-Chronic Lead Performance/Multiple MRI
Study Status Progress Adequate
General Study Protocol Parameters
Study Design Prospective Cohort Study
Study involve follow-up of premarket cohort (Y/N) Yes
Data Source Sponsor Registry
Comparison Group Objective Performance Criterion
Analysis Type Analytical
Study Population Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21

OSB Lead-Chronic Lead Performance/Multiple MRI Schedule

Report Schedule
Date Due
FDA Receipt
Reporting Status
six month report 08/09/2011 08/05/2011 On Time
1 year report 02/08/2012 02/02/2012 On Time
18 month report 08/08/2012 08/06/2012 On Time
2 year report 02/07/2013 02/05/2013 On Time
30 month report 08/08/2013 07/12/2013 On Time
3 year report 02/07/2014 02/05/2014 On Time
42 month report 08/07/2014 08/07/2014 On Time
4 year report 02/07/2015 02/09/2015 Overdue/Received
54 month report 08/08/2015 08/07/2015 On Time
5 year report 02/07/2016 02/08/2016 Overdue/Received
66 month report 08/07/2016 08/05/2016 On Time
6 year report 02/06/2017    

Show All Studies